Comparative antitumor activity of 5-fluorouracil and 5′-deoxy-5- fluorouridine in combination with interferon-α in renal cell carcinoma cell lines

Urologia Internationalis

Volumn 73, Issue 4, 2004, Pages 348-353

  Ikemoto, Shinichi ^a   Sugimura, Kazunobu ^a   Yoshida, Naomasa ^a   Kuratsukuri, Katsuyuki ^a   Wada, Seiji ^a   Nakatani, Tatsuya ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 Deoxy 5 fluorouridine; 5 Fluorouracil; Interferon ; Renal cell carcinoma; Thymidine phosphorylase

Indexed keywords

DOXIFLURIDINE; FLUOROURACIL; RECOMBINANT ALPHA INTERFERON;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSTASIS; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG SCREENING ASSAYS, ANTITUMOR; FLOXURIDINE; FLUOROURACIL; HUMANS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 10844260505     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081597     Document Type: Article

References (28)

1. Linehan MW, Shipley WU, Parkinson DR: Cancer of the kidney and ureter; in De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer. Principles and Practice of Oncology. Philadelphia, Lippincott-Raven, 1977, pp 1271-1299.
2. Yagoda A, Abi-Rached B, Petrylak D: Chemotherapy for renal cell carcinoma: 1983-1993. Semin Oncol 1995;22:42-60.
3. Swanson DA: Is cytotoxic chemotherapy effective in the treatment of advanced renal cell carcinoma? Semin Urol 1993;11:35-40.
4. Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik PH: Fluorouracil and recombinant α-2a-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 1989;7:1769-1775.
5. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH: In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracilsensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982;42:450-456.
6. Schwartz EL, Hoffman M, O'Connor CJ, Wadler S: Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cells. Biochem Biophys Res Commun 1992;182:1232-1239.
7. Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 1990;50:3474-3486.
8. Kelsen D, Lovett D, Wong J, Saltz L, Buckley M, Murray P, Heelan R, Lightdale C: Interferon α-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. J Clin Oncol 1992;10:269-274.
9. Greco FA, Figlin R, York M, Einhorn L, Schilsky R, Marshall EM, Buys SS, Froimtchuk MJ, Schuller J, Schuchter L, Buyse M, Ritter L, Man A, Yap AKL: Phase III randomized study to compare interferon α-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol 1996;14:2674-2681.
10. Pazdur R, Ajani JA, Winn R, Bearden J, Belt RJ, Pilat S, Hallinan R, Levin B: A phase II trial of 5-fluorouracil and recombinant α-2ainterferon in previously untreated metastatic gastric carcinoma. Cancer 1992;69:878-882.
11. Fossa SD: Interferon in metastatic renal cell carcinoma. Semin Oncol 2000;27:187-193.
12. Bukowski RM: Cytokine combinations: Therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol 2000;27:204-212.
13. Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T, Ishitsuka H: Preparation of antihuman thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 1996;19:1407-1411.
14. Schwartz EL, Baptiste N, Wadler S, Makower D: Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 1995;270:19073-19077.
15. Makower D, Wadler S, Haynes H, Schwartz EL: Interferon induced thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo. Clin Cancer Res 1997;3:923-929.
16. Chu E, Zinn S, Boarman D, Allegra CJ: Interaction of Á-interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 1990;50:5834-5840.
17. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, Maruyama H: Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Jpn J Cancer Res 1980;71:112-123.
18. Patterson AV, Zhang H, Moghaddam M, Bicknell R, Talbot DC, Stratford IJ, Harris AL: Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br J Cancer 1995;72:669-675.
19. Morita T, Matsuzaki A, Tokue A: Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA. Int J Cancer 2001;92:451-456.
20. Eda H, Fujimoto K, Watanabe S, Ishikawa T, Ohiwa T, Tatsuno K, Tanaka Y, Ishitsuka H: Cytokines induce uridine phosphorylase in mouse colon 26 carcinoma cells and make the cells more susceptible to 5′-deoxy-5-fluorouridine. Jpn J Cancer Res 1993:84:341-347.
21. Tevaearai HT, Laurent PL, Suardet L, Eliason JF, Givel JC, Odartchenko N: Interactions of interferon-α2a with 5′-deoxy-5-fluorouridine in colorectal cancer cells in vitro. Eur J Cancer 1992;28:368-372.
22. Laurent PL, Tevaearai HT, Eliason JF, Givel JC, Odartchenko N: Interferon α and 5′-deoxy-5-fluorouridine in colon cancer: Effects as single agents and in combination on growth of xenograft tumors. Eur J Cancer 1994;30:1859-1865.
23. Yamamoto Y, Toi M, Tominaga T: Prediction of the effects of 5′-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients. Oncol Res 1996;3:863-865.
24. Morita T, Tokue A: Biomodulation of 5-fluorouracil by interferon-α in human renal carcinoma cells: Relationship to the expression of thymidine phosphorylase. Cancer Chemother Pharmacol 1999;44:91-96.
25. Yoshimura A, Kuwazuru Y, Furukawa T, Yoshida H, Yamada K, Akiyama S: Purification and tissue distribution of human thymidine phosphorylase: High expression in lymphocytes, reticulocytes and tumors. Biochem Biophys Acta 1990;1034:107-113.
26. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T: Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in human breast cancer. Int J Cancer 1995;64:79-82.
27. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, Yamada Y, Murata F, Aikou T: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996;88:1110-1117.
28. Imazono Y, Takebayashi Y, Nishiyama K, Akiba S, Miyadera K, Yamada Y, Akiyama S, Ohi Y: Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J Clin Oncol 1997;15:2570-2578.